DySIS Medical Ltd, a medical devices company active within Women's
Health, today announces that Robert Cascella has joined as Chairman of
the board of directors of the Company effective January 2014. His
appointment further strengthens the board following a year of investment
and growth in 2013.
Mr. Cascella was previously Chief Executive Officer and President of
Hologic Inc., a leading manufacturer and supplier of diagnostic
products, medical imaging systems, and surgical products for Women's
Healthcare, between 2003 and 2013. He has over 30 years of senior
management, operational and finance experience. Prior to Hologic, Mr.
Cascella served as Managing Partner of CFG Capital LLC, an investment
banking firm specialising in healthcare and was the Chief Operating
Officer and Vice President of Finance at NeoVision Corporation, a
developer of 3D ultrasound technology used for real-time guidance of
interventional breast procedures.
Alastair Atkinson, CEO of DySIS Medical, said: "We welcome Robert as
Chairman. His industry knowledge, market and technology expertise and
extensive connections in the Women's Healthcareindustry add substantial
value to our team. I look forward to working with him to move DySIS into
the next stage of growth and expansion.
"I look forward to working with Alastair and the team on the
commercialisation strategy of a technology capable of significantly
improving upon the diagnostic protocols for cervical disease," Mr.
Cascella added. "DySIS has the unique opportunity to increase the
effectiveness of the current standard of care in developed markets,
while potentially addressing an unmet healthcare need in emerging
markets, where the diagnosis and treatment of cervical disease remains
DySIS Medical, a medical devices company active within Women's Health,
has developed an advanced cervical scan which, in addition to performing
traditional colposcopy examinations, uses dynamic spectral imaging to
scan, quantify and map the cervix.
Notes to Editors
DySIS Medical Ltd
DySIS Medical Ltd has its global headquarters in Edinburgh. The company
is committed to saving lives through the early detection and diagnosis
of disease using biophotonic innovations. It aims to be the global
leader in automated optical molecular imaging technologies for medical
diagnostic and screening applications. For more information, please
The DySIS product employs advanced photonics and computer assistance to
quantify and map the cervix during the aceto-whitening process. The
product is CE marked and commercially available in Europe. It is also
cleared to market in the USA by the FDA under the 510(k) programme as a
digital colposcope designed to image the cervix and lower genital tract
under illumination and magnification. Colposcopy is indicated for women
with an abnormal Pap smear in order to affirm normality or detect
abnormal appearances consistent with neoplasia, often with directed
[ Back To NFVZone's Homepage ]